UIA
LFCR icon

Ulland Investment Advisors’s Lifecore Biomedical LFCR Stock Holding History

Ulland Investment Advisors’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3K Hold
500
– – ﹤0.01% 212
2026
Q1 		$2K Hold
500
– – ﹤0.01% 204
2025
Q4 		$4K Hold
500
– – ﹤0.01% 194
2025
Q3 		$4K Buy
+500
New +$3.78K ﹤0.01% 205

Other funds holding LFCR

CA
CWC Advisors Lake Oswego, Oregon $225M AUM 23.94% 1-Year Est. Return
DT
DBA Trading Fort Lauderdale, Florida $199M AUM
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
MAA
Mraz Amerine & Associates Modesto, California $697M AUM 19.37% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Ulland Investment Advisors's LFCR Position: Q2 2026 in Review

Ulland Investment Advisors held its Lifecore Biomedical (LFCR) position steady in Q2 2026 at 500 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #212.

Ulland Investment Advisors first reported a position in LFCR in Q3 2025 and has held it in 4 quarters since. The position peaked at $4K in Q4 2025. 17 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • Ulland Investment Advisors held 500 shares of Lifecore Biomedical worth $3K as of Q2 2026.
  • Ulland Investment Advisors left its Lifecore Biomedical share count unchanged in Q2 2026.
  • Lifecore Biomedical made up ﹤0.01% of Ulland Investment Advisors's portfolio in Q2 2026, its #212 holding.
  • Ulland Investment Advisors first reported a position in Lifecore Biomedical in Q3 2025 and has held it in 4 quarters since.
  • Ulland Investment Advisors's Lifecore Biomedical position peaked at $4K in Q4 2025.
  • 17 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on Ulland Investment Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.